Renal Cell Carcinoma
JAMA · 24.09.2024 · 332 (12) · 1001
DOI: 10.1001/jama.2024.12848 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 24.09.2024. Verfasst von Tracy L Rose und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 427-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Renal cell carcinoma (RCC) is a common malignancy, with an estimated 434 840 incident cases worldwide in 2022. In the US, it is the sixth most common cancer among males and ninth among females. Observations Clear cell RCC is the most common histologic subtype (75%-80% of cases) and is characterized by inactivation of the von Hippel Lindau ( VHL ) tumor suppressor gene. Many patients (37%-61%) are diagnosed with RCC incidentally on an abdominal imaging study such as ultrasound or computed tomographic scan, and 70% of patients have stage I RCC at diagnosis. Although its incidence has increased approximately 1% per year from 2015 through 2019, the mortality rate of RCC has declined about 2% per year in the US from 2016 through 2020. Patients with a solid renal mass or complex cystic renal mass should be referred to urology. Treatment options for RCC confined to the kidney include surgical resection with partial or radical nephrectomy, ablative techniques (eg, cryoablation, radiofrequency ablation, radiation), or active surveillance for some patients (especially those with renal masses <2 cm). For patients with renal masses less than 4 cm in size (48% of patients), partial nephrectomy can result in a 5-year cancer-specific survival of more than 94%. For advanced or metastatic RCC, combinations of immune checkpoint inhibitors or the combination of immune checkpoint inhibitors with tyrosine kinase inhibitors are associated with tumor response of 42% to 71%, with a median overall survival of 46 to 56 months. Conclusions and Relevance RCC is a common malignancy that is often diagnosed incidentally on an abdominal imaging study. Seventy percent of patients are diagnosed with stage I RCC and 11% of patients with stage IV. First-line treatments for early-stage RCC are partial or radical nephrectomy, which can result in 5-year cancer-specific survival of more than 94%, ablative techniques, or active surveillance. New treatment options for patients with metastatic RCC include immune checkpoint inhibitors and tyrosine kinase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill.
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.
- Department of Genetics, University of North Carolina at Chapel Hill.
- Department of Pharmacology, University of North Carolina at Chapel Hill.
Förderung
- NCI NIH HHS
Zitieren
APA
Rose, T. L., & Kim, W. Y. (2024). Renal Cell Carcinoma. JAMA, 332(12), 1001. https://doi.org/10.1001/jama.2024.12848
Vancouver
Rose TL, Kim WY. Renal Cell Carcinoma. JAMA. 2024;332(12):1001. doi:10.1001/jama.2024.12848
BibTeX
@article{Rose2024,
author = {Rose, Tracy L and Kim, William Y},
title = {Renal Cell Carcinoma},
journal = {JAMA},
year = {2024},
volume = {332},
number = {12},
pages = {1001},
doi = {10.1001/jama.2024.12848}
}
EUVIMED